Substituted azaindazole compounds

摘要

Disclosed are azaindazole compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein: Q is: (i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or (ii) 9- to 10-membered bicyclic heteroaryl selected from Formula (II) and; wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; and R1, R2, R3, and Rg are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.;

主权项

1. A compound of Formula (I):or pharmaceutically acceptable salts thereof, wherein:
Q is:
(i) 5-membered heteroaryl comprising at least one nitrogen heteroatom and substituted with zero to 2 Rg; or(ii) 9- to 10-membered bicyclic heteroaryl selected from wherein Ring A is a 5- to 6-membered aryl or heteroaryl fused ring substituted with zero to 2 Rg; R1 is:
(i) H, halo, —CN, —ORd, —NReRe, or —C(O)ORf;(ii) C1-6alkyl substituted with zero to 4 Ra;(iii) C3-6 cycloalkyl substituted with zero to 4 Ra;(iv) aryl substituted with zero to 6 Rb;(v) heterocyclyl substituted with zero to 6 Rc; or(vi) heteroaryl substituted with zero to 6 Rc; R2 is:
(i) C1-6alkyl substituted with zero to 4 Ra′ where each Ra′ is independently halo, —OH, —CN, C3-6 cycloalkyl, C1-2 fluoroalkyl, C1-6 alkoxy, C1-2 fluoroalkoxy, —NRfRf, phenoxy substituted with zero to 4 Rb, heterocyclyl substituted with zero to 4 Rc, and/or heteroaryl substituted with zero to 4 Rb;(ii) C3-6 cycloalkyl substituted with zero to 4 Ra;(iii) —S(O)2(C1-4alkyl), —S(O)2(C1-4fluoroalkyl), or —C(O)(C1-6alkyl);(iv) aryl substituted with zero to 6 Rb;(v) heterocyclyl substituted with zero to 6 Rc; or(vi) heteroaryl substituted with zero to 6 Rc; each Ra is independently halo, —OH, —CN, C3-6cycloalkyl, C1-2fluoroalkyl, C1-6alkoxy, C1-2fluoroalkoxy, —NRfRf, phenyl substituted with zero to 5 Rb, phenoxy substituted with zero to 4 Rb, heterocyclyl substituted with zero to 4 Rc, and/or heteroaryl substituted with zero to 4 Rb; each Rb is independently halo, —OH, —CN, C1-4alkyl, C3-6cycloalkyl, C1-2fluoroalkyl, C1-6alkoxy, C1-4fluoroalkoxy, —NRfRf, —C(O)OH, —S(O)2(C1-4alkyl), —S(O)2NRfRf, and/or heterocyclyl substituted with zero to 4 Rc; each Rc is independently halo, —CN, —OH, C1-4alkyl, C3-6cycloalkyl, C1-2fluoroalkyl, C1-6alkoxy, C1-4fluoroalkoxy, —NRfRf, azetidine, and/or pyrrolidine, or two Rc attached to the same atom can form ═O; each Rd is:
(i) C1-4alkyl substituted with zero to 4 Ra;(ii) C3-6 cycloalkyl substituted with zero to 4 Ra;(iii) aryl substituted with zero to 6 Rb;(iv) heterocyclyl substituted with zero to 6 Rc; and/or(v) heteroaryl substituted with zero to 6 Rc; each Re is independently:
(i) H;(ii) C1-4alkyl substituted with zero to 4 Ra; and/or(iii) C3-6 cycloalkyl substituted with zero to 4 Ra; or two Re attached to the same nitrogen atom can form a 5-6 membered heterocyclyl ring having one additional heteroatom, and substituted with zero to 2 substituents independently selected from —CN, —OH, and/or C1-4alkyl: each Rf is independently H, C1-6alkyl, C3-6cycloalkyl, C1-4fluoroalkyl, and/or aryl; and each Rg is independently:
(i) halo, —CN, —ORd, —NReRe, or —C(O)ORf;(ii) C1-6alkyl substituted with zero to 4 Ra;(iii) C3-6 cycloalkyl substituted with zero to 4 Ra;(iv) aryl substituted with zero to 6 Rb;(v) heterocyclyl substituted with zero to 6 Rc; or(vi) heteroaryl substituted with zero to 6 Rc.